BIOMERICA INC (BMRA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.31+4.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improves toward break-even: metric not reported.
Biomerica aims to improve operating income and grow revenue. Revenue was $987,000 in Q3 2026. Operating loss was $1.3 million in Q3 2026. The company has new M&A activity that could help growth.
Revenue is falling fast, down from $1.38 million to $987,000. Operating losses are growing worse, not better. The company is still losing money and risky.
The market expects revenue to shrink about 38% next year. Our fair value is near $6.75, reflecting this decline. We see risk if revenue falls more or losses grow.
Breaks if: M&A fails to improve revenue or profit within 1 year
Breaks if: Operating loss worsens or stays below -$1.3M next year
YoY revenue growth falls below 0% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The current thesis is cautious, given the company's recent weak financial performance and high risk profile.
The market appears to price BMRA as cheap compared to its peers, with an expectations gap indicating that investors may be anticipating further challenges. The valuation suggests that the current sentiment is somewhat justified, but there is a divergence from industry norms.
Fundamentals are likely to remain weak in the near term, as management struggles to improve operating income and revenue growth. The company has consistently missed expectations, which raises the risk of further earnings misses.
The future performance of BMRA hinges on broader healthcare sector trends, particularly the performance of major players like ABT, MDT, and SYK. Additionally, the company's ability to manage capital allocation effectively and reverse its revenue decline will be critical.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company priced a $2.23 million private placement at $1.60. This may dilute existing shares and impact operating income.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, BMRA faces significant challenges that could impact its performance. Monitoring sector trends and management execution will be essential. Not investment advice.